This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Molecular Partners Ag. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Sebastian Grimm: Innovator in Multi-Specific T-Cell Engagers
Introduction
Sebastian Grimm is a notable inventor based in Schlieren, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of multi-specific proteins for therapeutic applications.
Latest Patents
Sebastian Grimm holds a patent for "DARPin based multi-specific t-cell engagers." This invention relates to recombinant multi-specific proteins that comprise binding agents with specificity for various targets, including CD3, CD33, CD123, and CD70. The patent also covers nucleic acids encoding these multi-specific proteins, pharmaceutical compositions containing them, and their use in treating or diagnosing diseases such as acute myeloid leukaemia (AML) in mammals, including humans.
Career Highlights
Grimm is associated with Molecular Partners AG, a company that focuses on innovative biopharmaceuticals. His work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.
Collaborations
Some of his notable coworkers include Nina Reschke and Christian Reichen, who contribute to the collaborative efforts at Molecular Partners AG.
Conclusion
Sebastian Grimm's innovative work in the field of multi-specific t-cell engagers exemplifies the potential of biotechnology in addressing complex medical challenges. His contributions continue to pave the way for advancements in cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile